TL;DR
This study compares the electrocardiogram (ECG) characteristics of two implantable cardiac monitors (ICMs), Reveal LINQ I and BIOMONITOR III, to assess their impact on event detection accuracy. The BIOMONITOR III demonstrated significantly higher R-wave amplitude and a greater likelihood of detecting P-waves, which are crucial for accurate diagnosis of arrhythmias, particularly atrial fibrillation.
What Problem Does This Paper Address?
Implantable cardiac monitors (ICMs) are vital tools for detecting cardiac rhythm abnormalities like tachycardias, bradycardias, and atrial fibrillation. However, a persistent challenge with these devices is the occurrence of "undersensing" (missing actual events) and "oversensing" (falsely detecting events), which can compromise diagnostic accuracy. While complex algorithms are employed to minimize these issues, subtle differences in the ECG characteristics captured by various ICMs may contribute to variations in their performance. This paper aims to investigate how the ECG signal quality, specifically R-wave amplitude and P-wave detectability, from two commercially available ICMs influences the correct adjudication of recorded events and the reduction of undersensing and oversensing.
Methods
The researchers conducted a comparative analysis of two implantable loop monitors: the Reveal LINQ I (Medtronic) and the BIOMONITOR III (Biotronik). They utilized two distinct patient cohorts:
- Cohort 1 (Paired Design): This cohort consisted of 30 patients who initially had a Reveal LINQ I implanted. When the LINQ I reached its end-of-life, it was replaced with a BIOMONITOR III at the exact same implantation site. This unique design allowed for a direct comparison of ECGs from both devices within the same patient, minimizing confounding variables.
- Cohort 2 (Retrospective Design): This larger cohort included 106 patients who had either a Reveal LINQ I or a BIOMONITOR III implanted at the physician's discretion over a two-year period.
For both cohorts, the researchers analyzed key ECG parameters:
- R-wave amplitude: Measured at the time of implant.
- Presence of a visible P-wave: Assessed in sinus rhythm.
- Frequency of undersensing and oversensing episodes: Determined by analyzing R-R interval variability and identifying missed or falsely detected events.
Data analysis involved paired and standard t-tests for R-wave amplitude comparisons and chi-squared tests for P-wave presence and event adjudication.
Datasets
The study utilized data from two patient cohorts:
- Cohort 1: 30 patients who underwent sequential implantation of Reveal LINQ I followed by BIOMONITOR III.
- Cohort 2: 106 patients who received either a Reveal LINQ I or a BIOMONITOR III.
The paper does not introduce new benchmark datasets.
Key Insights and Ideas
- P-waves are critical for accurate diagnosis: The study strongly suggests that the ability to reliably detect P-waves is paramount for correctly adjudicating arrhythmias, especially atrial fibrillation. The presence of a P-wave was found to be decisive in correctly identifying AF episodes.
- Device size matters for signal quality: The BIOMONITOR III, being a physically larger device with a larger recording dipole, consistently produced a stronger R-wave signal compared to the smaller LINQ I. This enhanced signal quality is likely a key factor in its improved performance.
- R-wave amplitude and P-wave detection are linked: The study observed that the BIOMONITOR III's greater R-wave amplitude was associated with a higher likelihood of detecting P-waves, highlighting a potential synergistic effect for improved diagnostic capability.
- Algorithm limitations persist: Despite advancements in ICM algorithms, undersensing and oversensing remain challenges. The study found that even with reprogramming, these issues could not always be resolved, underscoring the importance of inherent signal quality.
Key Results
- R-wave Amplitude: In Cohort 1, the BIOMONITOR III showed a significantly higher mean R-wave amplitude (0.98 ± 0.4 mV) compared to the LINQ I (0.35 ± 0.2 mV) (P = .001). Similarly, in Cohort 2, the BIOMONITOR III (0.65 ± 0.37 mV) had a greater mean R-wave than the LINQ I (0.48 ± 0.38 mV) (P = .02).
- P-wave Detection: A visible P-wave in sinus rhythm was detected in a significantly higher percentage of patients with the BIOMONITOR III (93% in Cohort 1, 62.26% in Cohort 2) compared to the LINQ I (63% in Cohort 1, 30.18% in Cohort 2) (P = .004 and P = .01, respectively).
- Undersensing: No significant difference in undersensing was observed between the two devices in either cohort (P > .5 in Cohort 1, P = .08 in Cohort 2).
- Oversensing: In Cohort 1, the LINQ I exhibited a higher incidence of oversensing (13.33%) compared to the BIOMONITOR III (0%) (P = .012). This difference was not statistically significant in Cohort 2.
Limitations and Future Work
The authors acknowledge several limitations:
- Small Sample Size (Cohort 1): The limited number of patients in the paired cohort may have reduced the statistical power to detect correlations between R-wave amplitude and undersensing/oversensing.
- Temporal Effect (Cohort 1): The sequential implantation (LINQ I followed by BIOMONITOR III) in Cohort 1 raises the possibility of a temporal effect influencing recording quality, independent of the device itself.
- Unequal Follow-up (Cohort 1): The difference in follow-up duration between the two devices in Cohort 1 could impact the observed number of events.
- Retrospective Nature (Cohort 2): The retrospective design of Cohort 2 is subject to potential confounding factors.
Future work could involve larger, prospective studies to further validate these findings. The authors emphasize that while advanced algorithms are crucial, they cannot fully compensate for inherent signal quality issues. Future research could explore how to optimize ICM implantation sites based on individual patient factors (like BMI) to maximize signal quality and diagnostic accuracy.
Summary updated